Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety follow-up after RP1, RP2, or RP3 treatment
2025-521621-33-00Phase 4Authorised
- Sponsor
- Replimune Group, Inc.
- Start
- Mar 2026
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 4, open-label trial of vusolimogene oderparepvec, sturlimogene erparepvec and RP3 in hepatocellular carcinoma (HCC), melanoma and Nonhematologic neoplasms (3 cohorts), sponsored by Replimune Group, Inc. Primary endpoints: Delayed adverse events and Herpetic infection and RPx detection. Planned start Mar 2026; status: authorised.
02
Drugs
vusolimogene oderparepvecsturlimogene erparepvecRP3
03
Conditions
hepatocellular carcinoma (HCC)melanomaNonhematologic neoplasms
Beyond the preview
Go deeper on 2025-521621-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521621-33-00.